rss
Evid Based Mental Health 1:116 doi:10.1136/ebmh.1.4.116
  • Therapeutics

Metrifonate was effective in mild to moderate Alzheimer's disease

Metrifonate v placebo at 26 weeks in patients with Alzheimer's disease†

Outcomes Metrifonate Placebo RRI (95% CI) NNH (CI)
†Abbreviations defined in glossary; RRI, NNH, and CI calculated from data in article.
Dropouts 21% 12% 79% (9 to 200) 11 (7 to 65)
Dropouts from adverse events 12% 4% 180% (25 to 541) 13 (8 to 46)

This Article

  1. Extract
  2. Full text

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.